

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: TCA-13144	Serial No.: 10/578,943
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))		Applicant: Soo-Hyun Kim <i>et al.</i>		
		Filing or 371(c) Date: 11/09/2006	Group Art Unit: 1647	

U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	Document / Patent Number	Publication / Issue Date	Applicant / Patente	Class	Subclass	Filing Date
OIPE	1	6,277,969	08/21/2001	Le <i>et al.</i>	536	23.1	08/12/1998
MAR 07 2008 PATENT & TRADEMARK OFFICE USPTO	2	6,448,380	09/10/2002	Rathjen <i>et al.</i>	530	388.23	12/13/2000
	3	6,572,852	06/03/2003	Smith <i>et al.</i>	424	85.2	01/12/2001
	4	6,605,280	08/12/2003	Novick <i>et al.</i>	424	184.1	10/12/2000
	5	6,706,491	03/16/2004	Chang <i>et al.</i>	435	29	11/29/1999
	6	6,989,262	01/24/2006	Bejanin <i>et al.</i>	435	226	11/13/2001
	7	2003/0087270	05/08/2003	Schlegel <i>et al.</i>	435	6	06/12/2002
	8	2003/0092616	05/15/2003	Matsuda <i>et al.</i>	514	12	05/24/2002
	9	2003/0148316	08/07/2003	Lipford <i>et al.</i>	435	6	08/01/2002
	10	2003/0154032	08/14/2003	Pittman <i>et al.</i>	702	20	12/17/2001
	11	2005/0048490	03/03/2005	Azimzai <i>et al.</i>	435	6	09/26/2002
	12	2005/0130145	06/16/2005	Yue <i>et al.</i>	435	6	10/03/2002
	13	2005/0208496	09/22/2005	Ohtani <i>et al.</i>	435	6	07/31/2003
	14	2006/0088532	04/27/2006	Alitalo <i>et al.</i>	424	145.1	03/07/2003

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
	15	WO 01/064886	09/07/2001	WIPO				
	16	WO 02/059260	08/01/2002	WIPO				
	17	WO 02/083898	10/24/2002	WIPO				
	18	WO 02/096943	12/05/2002	WIPO			X	
	19	WO 03/080640	10/02/2003	WIPO				
	20	WO 2005/016962	02/24/2005	WIPO				
	21	WO 2006/071088	07/06/2006	WIPO				
	22	EP 1487857	12/22/2004	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

23	Banda <i>et al.</i> , "Mechanisms of effects of complement inhibition in murine collagen-induced arthritis," <i>Arthritis Rheum</i> , 46:3065, 2002
24	Banda <i>et al.</i> , "Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein," <i>J Immunol</i> , 170:2100-2105, 2003
25	Bendele <i>et al.</i> , "Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis," <i>Arthritis Rheum</i> , 43:2648-2659, 2000
26	Bernot <i>et al.</i> , "A transcriptional map of the FMF region" <i>Genomics</i> , 50:147-160, 1998
27	Cohen, "Systemic Autoimmunity," in Paul (ed.) <i>Fundamental Immunology</i> , Lippincott-Raven Publishers: Philadelphia, pp. 1067-1088, 1999
28	Dahl <i>et al.</i> , "Identification of a novel gene expressed in activated natural killer cells and T cells," <i>J Immunol</i> , 148:597-603, 1992
29	Davis <i>et al.</i> , "Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update," <i>Ann Rheum Dis</i> , 59 Suppl 1:i41-3, 2000
30	Faggioni <i>et al.</i> , "IL-18-binding protein protects against lipopolysaccharide-induced lethality and prevents the development of Fas/Fas ligand-mediated models of liver disease in mice," <i>J Immunol</i> , 167:5913-5920, 2001
31	Firestein, "Rheumatoid Arthritis," in <i>Scientific American Medicine</i> , 2000

Examiner:	Date Considered:
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: TCA-13144	Serial No.: 10/578,943
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))		Applicant: Soo-Hyun Kim <i>et al.</i>	
Filing or 371(c) Date: 11/09/2006		Group Art Unit: 1647	

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.